Skip to main content
News

Anti-nausea Patch Shortage Begins


September 22, 2016

The US Food and Drug Administration (FDA) announced that Sandoz is experiencing a shortage of scopolamine (Transderm Scop) transdermal system patch.

The causes that prompted the shortage are listed below.

 

Presentation

Availability

Shortage Reason

NDC

1.5 mg patch, 10 count

Intermittent backorder until December 2016

Demand increase

10019-553-01

1.5 mg patch, 24 count

Unavailable. Limited availability expected from mid-October to December 2016

Requirements related to complying with good manufacturing practices

10019-553-02

1.5 mg patch, 4 count

Intermittent backorder until December 2016

Shipping delay

0067-4345-04

 

__________________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Hormone Shortage Begins
Drug Shortage Prompts Temporary Importation

__________________________________________________________________________________________________________________________________________________________________________

In July, the FDA reported that it was working with Sandoz to help alleviate a shortage of L-cysteine hydrochloride injection. The company began importing the medication from its sister company in Canada.

Sandoz has also had several recalls in the recent past, including the recall of more than 78,000 bottles of dicloxacillin sodium capsules. Additionally, the company recalled more than 300,000 tablets of lisinopril.

 

--Stephanie Vaccaro

 

Reference:

US Food and Drug Administration. FDA drug shortages. www.fda.gov. Accessed September 20, 2016.

 

Back to Top